Edition:
United Kingdom

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.55USD
5:23pm GMT
Change (% chg)

$-0.01 (-2.65%)
Prev Close
$0.56
Open
$0.57
Day's High
$0.57
Day's Low
$0.55
Volume
32,834
Avg. Vol
54,857
52-wk High
$1.38
52-wk Low
$0.49

Summary

Name Age Since Current Position

Katrine Bosley

50 2013 Chairman of the Board

William Clark

55 2011 President, Chief Executive Officer, Director

Michael Alfieri

53 2018 Principal Financial Officer and Principle Accounting Officer, Vice President - Finance

John Bishop

54 2016 Executive Vice President - Pharmaceutical Sciences

Narinderjeet Singh

2018 Senior Vice President - Pharmaceutical Sciences and Manufacturing

Jessica Flechtner

44 2016 Chief Scientific Officer

Derek Meisner

2018 General Counsel

Girish Aakalu

2018 Chief Business Officer

Thomas Davis

52 2018 Chief Medical Officer

Eric Hoffman

47 2014 Chief Business Officer

Ali Behbahani

41 2018 Director

Ronald Cooper

55 2016 Director

George Siber

2007 Director

Kenneth Bate

67 2014 Independent Director

Michael Higgins

55 2015 Independent Director

Howard Mayer

2017 Independent Director

Biographies

Name Description

Katrine Bosley

Ms. Katrine S. Bosley is Chairman of the Board of the company. She has served as a member of our board of directors since March 2013 and as our chairperson since August 2013. Ms. Bosley is the Chief Executive Officer of Editas Medicine Inc. ("Editas"), a position to which she was appointed in June 2014. Prior to Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from September 2013 to May 2014. She served as Chief Executive Officer of Avila Therapeutics Inc. ("Avila"), from May 2009 to March, 2012, when Avila was acquired by Celgene Corporation. Before Avila, she was Vice President, Strategic Operations at Adnexus Therapeutics Inc. ("Adnexus"), a Bristol-Myers Squibb Company and was Vice President, Business Development at Adnexus before that. She joined Adnexus from Biogen Idec where she held roles in business development, commercial operations, and portfolio strategy in the United States and Europe and led the in-licensing of Tysabri (natalizumab) among a number of other transactions. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners from 1993 to 1995. In addition to serving as a director of our Company, Ms. Bosley currently serves as a director of Galapagos NV and Scholar Rock LLC. She also is a member of the BIO Governing Board for Emerging Companies. Ms. Bosley graduated from Cornell University with a B.A. in Biology.

William Clark

Mr. William Clark is President, Chief Executive Officer, Director of the Company. He has served as our President and Chief Executive Officer since February 2011. Previously he served as our Chief Business Officer from August 2010 to February 2011. Mr. Clark has served on our board of directors since February 2011. Prior to joining our Company, he served as Chief Business Officer at Vanda Pharmaceuticals, Inc. ("Vanda"), a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company’s strategic and business development activities, and played a central role in raising more than $220 million in multiple public and private financings. Prior to Vanda, Mr. Clark was a principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham (now GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Michael Alfieri

Mr. Michael Alfieri is Principal Financial Officer and Principle Accounting Officer, Vice President - Finance of the company. He has been Vice President of Finance of the Company since May 2018 and will retain this position. Before joining the Company, Mr. Alfieri served as Vice President of Finance of Radius Health, Inc. from January 2017 through May 2018, Corporate Controller of Merrimack Pharmaceuticals, Inc. from July 2014 through January 2017, and Executive Director of Finance and Corporate Controller at Anika Therapeutics, Inc.

John Bishop

Dr. John E. Bishop is Executive Vice President - Pharmaceutical Sciences of the Company. He joined Genocea in May 2016 as Executive Vice President of Pharmaceutical Sciences. Prior to joining Genocea, Dr. Bishop was Vice President (2004-2006) and then Senior Vice President (2006-2016) of Pharmaceutical Sciences at Momenta Pharmaceuticals. At Momenta, he was responsible for all aspects of chemistry, manufacturing, and controls (CMC) across an array of novel, generic, and biosimilar products, including the landmark approval and launch of generic versions of the complex products Lovenox® and Copaxone®. Before Momenta, Dr. Bishop spent a combined 13 years in various roles of increasing scope and responsibility at Millennium Pharmaceuticals as CMC Leader of Velcade ®; DuPont Phamaceuticals; and Alcon Laboratories, where he co-invented the anti-glaucoma drug Travatan®. He holds a Ph.D. in Organic Chemistry from the University of California, Berkeley, an M.B.A. from Northeastern University, and a B.S. in Chemistry and German from Tufts University.

Narinderjeet Singh

Mr. Narinder Singh is Senior Vice President - Pharmaceutical Sciences and Manufacturing of the Company. Mr. Singh has more than 20 years of experience in process development, scale-up, technical operations and manufacturing supply chain of biopharmaceuticals. Prior to joining Genocea, Mr. Singh was Vice President of Drug Product Development and Manufacturing at Momenta Pharmaceuticals where he built an integrated drug product group to support Momenta's expanding portfolio of biosimilars and novel biologics pipeline. Prior to Momenta, Mr. Singh was at Amgen where he played a key role in development of Amgen's biologics-based pipeline and commercial drug products with a strong focus on process development, commercialization, manufacturing, and new technology development. Mr. Singh holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from Indian Institute of Technology, Delhi, an M.S. in Chemical Engineering from the University of Houston, and an M.B.A. from UCLA Anderson School of Management.

Jessica Flechtner

Dr. Jessica Baker Flechtner, Ph.D. is Chief Scientific Officer of the Company. She joined Genocea in 2007, soon after the company was founded, and currently serves as the Chief Scientific Officer. Dr. Flechtner is a pioneer in the development of novel vaccines directed toward T cell immunity, and has more than 20 years of experience in immunology, infectious disease, cancer, and vaccine development. She leads Genocea’s efforts to develop T cell-directed vaccines and immunotherapies against infectious diseases and other indications. Prior to joining Genocea, Dr. Flechtner developed vaccines and immunotherapies for cancer, infectious disease, autoimmunity and allergy in several companies including Mojave Therapeutics and Antigenics Inc. (now Agenus). She is an inventor on ten pending and four issued patents and has multiple peer-reviewed scientific publications. Dr. Flechtner performed her post-doctoral work at the Dana Farber Cancer Institute and Harvard Medical School. She holds a Ph.D. in Cellular Immunology and a B.S. in Animal Science from Cornell University, and is a member of the American Association of Immunologists, American Association for Cancer Research, Society for Immunotherapy of Cancer, and American Society for Microbiology.

Derek Meisner

Mr. Derek Meisner is General Counsel of the Company. Mr. Meisner brings broad legal expertise to Genocea as its first in-house General Counsel. He has extensive experience as a corporate attorney, previously serving as the General Counsel to multiple Boston-based financial services firms, including life science investor RA Capital, as well as serving as Partner at the international law firm K&L Gates and as Branch Chief in the Division of Enforcement of the U.S. Securities and Exchange Commission.

Girish Aakalu

Mr. Girish Aakalu, Ph.D. is Chief Business Officer of the company. Dr. Aakalu brings a broad skillset to Genocea, spanning business development, corporate and R&D strategy, product portfolio management, commercial planning, and alliance management, following positions at the Ipsen Group, a global specialty biopharmaceutical company, which included Vice President: Global Head of External Innovation, and positions at Pfizer, Inc., which included Executive Director: Head of Strategy, Innovation & Operations for Pfizer's External R&D Innovation team. His previous roles also include business development and oncology pipeline market planning positions at Genentech, Inc. and life science consulting experience at L.E.K Consulting. He received a B.A. in Biophysics from Johns Hopkins University and a Ph.D. in Cellular and Molecular Neurobiology from the California Institute of Technology.

Thomas Davis

Dr. Thomas Andrew Davis is Chief Medical Officer of the Company. Dr. Davis joins Genocea with over 20 years of academic and industry experience in immuno-oncology and cancer drug development. Most recently, he served as Chief Medical Officer of Gadeta B.V., a Dutch cell therapy company pursuing novel cancer targets, where he steered a novel cell therapy technology into first-in human clinical studies. He previously served as Chief Medical Officer of Celldex from 2006 to 2017, where he led all aspects of clinical and regulatory development including strategy, tactics, and execution. While at Celldex, Tom actively built and oversaw Clinical Science, Medical Affairs, Safety, Clinical Operations, Statistics, Regulatory Affairs, and Project Management, managed collaborations with large global pharmaceutical partners, and participated in investor relations activities. He also served as Chief Medical Officer at GenVec and as Senior Director of Clinical Science at Medarex. Prior to joining the industry, Dr. Davis supervised clinical efforts at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI), and worked on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, his M.S. in Physiology and his M.D. from Georgetown University, and completed a fellowship in medical oncology at Stanford University.

Eric Hoffman

Mr. Eric S. Hoffman is Chief Business Officer of the Company. Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014. Eric also held roles in investor relations and corporate communications whilst at Idenix. Prior to Idenix, Eric spent four years at Biogen Idec in investor relations and business development roles and spent six years on Wall Street as an equity research analyst at J.P. Morgan, Schwab Soundview Capital Markets and Bear Stearns. Before starting on Wall Street in 2001, he was a post-doctoral research scientist in the Department of Immunobiology at Guy's Hospital in London, studying T cell development. He has authored several book chapters and peer-reviewed papers, including in Cell,Immunity, and Genes & Development. He holds a Ph.D. in Immunobiology from Yale University and a B.S. in Biology from Trinity University.

Ali Behbahani

Dr. Ali Behbahani is Director of the company. He is currently a partner in the healthcare group at New Enterprise Associates (“NEA”). NEA was a lead investor in Genocea’s concurrent $55 million public offerings that were consummated in January 2018, making a total investment of $25 million to purchase a total of 25 million shares of the Company’s common stock and 25 million Class A warrants to purchase up to 12.5 million shares of the Company’s common stock. In connection with the offerings, the Company agreed to elect one representative from NEA to serve on the Board. The Company has no ongoing obligation to continue to nominate NEA’s representative on the Board. Dr. Behbahani has been at NEA since 2007, where he specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. Dr. Behbahani conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University. He concurrently earned his M.D. from The University of Pennsylvania School of Medicine and his M.B.A. from The University of Pennsylvania Wharton School, where he graduated with Honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in Biomedical Engineering, Electrical Engineering, and Chemistry from Duke University.

Ronald Cooper

Mr. Ronald Harold Wilfred Cooper is Director of the Company. He has served as a member of our board of directors since June 2016. Mr. Cooper is President and CEO of Albireo Pharma, a position that he was appointed in June 2015. Ron is a life sciences leader with a track record of growing and rejuvenating businesses, brands and organizations – ranging from entrepreneurial, resource-constrained, up to $4.5 billion – in the U.S. and Europe. Prior to Albireo, he was with Bristol-Myers Squibb for over 25 years working in five different countries and holding positions of increasing responsibility in sales, marketing and general management culminating in President of Europe. In Europe, he was responsible for over 30 countries with sales exceeding $4.5 Billion. While at BMS, Ron was directly associated with several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz® Sustiva® Sprycel®, and Yervoy® He has successfully completed over a dozen business development deals including the creation of the first single tablet HIV/AIDS regimen partnership. Ron is a graduate of St. Francis Xavier University in Canada.

George Siber

Dr. George Siber, M.D. is Director of the Company. He has served as a member of our board of directors since 2007. From 1996 to 2007, Dr. Siber served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines ("Wyeth"). While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar, a pneumococcal vaccine which has achieved multibillion dollar revenues; Acel-Imune, an acellular pertussis vaccine; and Meningitec, a meningococcal meningitis vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. During this time, Dr. Siber led the research and manufacturing of multiple vaccines and immune globulins including Respigam, a human immune globulin against respiratory syncytial virus. Since 2007, Dr. Siber has served on the boards of directors of several vaccine companies, including Crucell, Selecta Biosciences, Vedantra Pharmaceuticals and Affinivax Inc., and as a consultant or scientific advisory board member of ClearPath Vaccines Company, of which he is currently the Chief Scientific Officer, PaxVax, Vaxess Technologies, Inc., the Bill & Melinda Gates Foundation, PATH, the Wellcome Trust, the European Commission (on vaccinations), the National Institutes of Health, or NIH, and the Korean FDA. Dr. Siber serves as a member of the Board of Trustees of the International Vaccine Institute. Dr. Siber holds an M.D. degree from McGill University in Canada, received post-doctoral training in Internal Medicine at Rush-Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and Infectious Disease and vaccinology training at Children’s Hospital and Beth Israel Hospital, Harvard Medical School Boston.

Kenneth Bate

Mr. Kenneth M. Bate is Independent Director of the Company. He has served as a member of our board of directors since September 2014. Mr. Bate is currently a director of AVEO Pharmaceuticals, Catabasis Pharmaceuticals, Epizyme Inc and Vanda Pharmaceuticals. Mr. Bate previously served as President and Chief Executive Officer of Archemix Corp. and NitroMed Inc., Chief Financial Officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds a M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. from Williams College.

Michael Higgins

Mr. Michael J. Higgins is Independent Director of the Company. He has served as a member of our board of directors since February 2015. In January 2015, Mr. Higgins joined Polaris Venture Partners as an Entrepreneur-in-Residence. Prior to joining Polaris Venture Partners, Mr. Higgins served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals ("Ironwood") from 2003 through 2014, playing a key role in Ironwood’s evolution from a privately-funded discovery organization through its initial public offering and the launch of its first commercial product. Under his leadership, the company was able to raise more than one billion dollars to help support the development of the business during that period. Prior to his work at Ironwood, from 1997 through 2003, Mr. Higgins worked at Genzyme Corporation ("Genzyme") in a variety of leadership roles including Vice President, Corporate Finance and Vice President, Business Development. While at Genzyme, he was involved with multiple businesses including the Cell Therapy, Gene Therapy, and Orphan Disease business units. Previously, Mr. Higgins served as Chief Financial Officer of Procept, Inc., from 1992 to 1997 and led the company through its initial public offering. Mr. Higgins currently serves as a director of Pulmatrix, Inc. and Voyager Therapeutics. Mr. Higgins began his pharmaceutical career as a sales representative for Schering-Plough Corporation in 1986. Mr. Higgins earned his B.S. from Cornell University and holds a M.B.A. from the Amos Tuck School of Business at Dartmouth College.

Howard Mayer

Dr. Howard Mayer M.D. is Independent Director of the company. He has served as a member of our board of directors since March 2017. Dr. Mayer is currently senior vice president and head of global clinical development at Shire plc. Dr. Mayer joined Shire in 2012 and is responsible for global clinical development across hematology, immunology, oncology, genetic diseases, GI/metabolic, neuroscience and ophthalmology therapeutic areas. Previously he served as chief medical officer at EMD Serono, a division of Merck KGaA, since 2009. Prior to that, he held a variety of global roles at Pfizer Inc. including head of clinical development and medical affairs for Virology/Infectious Diseases. Prior to joining Pfizer, he served as director of Infectious Diseases Clinical Research at Bristol-Myers Squibb for five years. Dr. Mayer obtained his BA from the University of Pennsylvania and his M.D. from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the scientific advisory boards of Macrolide Pharmaceuticals, and Arsanis Biosciences, and has served on the board of Autism Speaks in New England since 2011 and on the board of the Melmark Charitable Foundation since 2016. In 2011, he was honored by PharmaVoice as one of the 100 Most Inspiring People in the Life Sciences Industry.